ATRC
AtriCureยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ATRC Profile
Atricure, Inc.
A leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management
Healthcare Equipment and Supplies
10/31/2000
08/05/2005
NASDAQ Stock Exchange
1,300
12-31
Common stock
7555 Innovation Way
, Mason
, OH 45040
--
AtriCure, Inc., a medical device company, provides innovative atrial fibrillation solutions to reduce the economic and social burden of atrial fibrillation, achieving superior results. The company's synergistic ablation system is the first and only device approved by the U.S. Food and Drug Administration for the treatment of long-lasting atrial fibrillation. The company has two main product lines in the ablation of cardiac tissue. The company's main product line is the ablation of cardiac tissue, which accounts for the vast majority of the company's revenue, the collaborative system bipolar ablation forceps system and related radiofrequency ablation equipment. The company also offers a frozen product line that features reusable equipment and one-time freezing. The company's AtriClip system is the world's most widely used implant for left atrial appendage management. The company believes that cardiothoracic surgeons using the company's ablation and left atrial appendage management device can reduce AFIB-related complications in the treatment of AFIB.
The company was incorporated in Delaware on October 31, 2000. The company is a leading partner in atrial fibrillation solutions, providing innovative products, professional education, and supporting clinical science to reduce the economic and social burden of AFIB. The company sells its products to hospitals worldwide through a direct sales force and distributors.
